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ABSTRACT
The insulin-like growth factor (IGF) axis plays key roles in normal tissue growth and development as well as in the progression of
several tumour types and their subsequent growth and progression to a metastatic phenotype. This review explores the role of IGF
system in normal germ cell development and function in addition to examining the evidence for deregulation of IGF signalling in
cancer, with particular relevance to evidence supporting a role in testicular germ cell tumours (TGCTs). Despite the clear preclinical
rationale for targeting the IGF axis in cancer, there has been a lack of progress in identifying which patients may benefit from such
therapy. Future employment of agents targeting the IGF pathway is expected to concentrate on their use in combination with other
treatments to prevent resistance and exploit their potential as chemo- and radiosensitizers.
INTRODUCTION
The insulin and insulin-like growth factor (IGF) signalling sys-
tem has been implicated in a vast array of both physiological
and pathological cellular processes. The IGF family principally
comprises three ligands (insulin, IGF1 and IGF2), three receptors
[the insulin receptor (IR), the insulin-like growth factor 1 recep-
tor (IGF1R) and the insulin-like growth factor 2 receptor
(IGF2R)] in addition to six high affinity ligand binding proteins
(IGFBP1-6), and accessory proteins such as IGFBP-specific pro-
teases. The signalling through IR/IGFR is complex (see Fig. 1).
IR and IGF1R are tyrosine kinase receptors that share a high
degree of structural homology and can exist as either homo- or
heterotetramers (hybrid receptors). Additional complexity arises
through alternative splicing of the INSR gene resulting in two IR
subunits IR-A and IR-B, which have differing affinities for insulin
and the IGF ligands (Seino & Bell, 1989). This results in a total of
seven different receptors. Insulin can signal through any recep-
tor containing at least one IR subunit while IGF1 can signal
through any receptor containing at least one IGF1R subunit.
IGF2 can signal through the same receptors as IGF1 in addition
to the IR-A homotetramer as well as the IGF2R homodimer (re-
viewed in Simpson et al., 2017). IGF2R is structurally unrelated
to IR/IGF1R and possesses no tyrosine kinase activity or
autophosphorylation sites. The IGF2R receptor can bind to G-
proteins, however, and despite previous assertions that IGF2R
functions only to control IGF2 ligand levels by acting as a sink
receptor, it is possible that it can initiate downstream signalling
(El-Shewy et al., 2007). While signalling through the IR-A/B and
IR-B receptors mainly contributes to glucose homeostasis, sig-
nalling through the IGF1R hetero- and homotetramers generally
leads to activation of both anti-apoptotic mechanisms resulting
in increased cell survival and increased cellular proliferation and
growth in normal and malignant tissues.
ROLE OF IGF SYSTEM IN TESTICULAR FUNCTION:
LESSONS LEARNED FROM GENETIC MODELS
Signalling through the insulin and Igfr receptors are absolutely
required for sex determination in mice (Nef et al., 2003). There is
complete XY sex reversal due to failure to upregulate Sry and a
complete failure of the testicular genetic programme in mouse
embryos with homozygous deletion of the Insr and Igf1r genes.
Ovarian differentiation is also delayed in XX gonads in the same
model, although the ovarian genetic programme is eventually
initiated several days later than in control embryos (Pitetti et al.,
2013a). It has subsequently been shown that specific ablation of
the Insr and Igf1r genes in Sertoli cells drastically influences tes-
tis size, Sertoli cell number and sperm production, whereas dele-
tion of these genes in just the germ cells themselves results in
normal testicular function and size (Pitetti et al., 2013b). The
same study showed that a disruption to the neonatal action of
536 Andrology, 2019, 7, 536–544 © 2019 The Institute of Cancer Research. Andrology published by Wiley Periodicals Inc on behalf of The
American Society of Andrology and European Academy of Andrology.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
[The license statement for this article was changed on 18 July, 2019 after original online publication.]
ISSN: 2047-2919 ANDROLOGY
follicle-stimulating hormone (FSH) on immature Sertoli cells
occurred in the absence of Insr/Igf1r (IIR) signalling. A more
recent study concluded that although foetal Leydig cell function
is normal, adult Leydig cells fail to mature using the constitutive
double knockout model (Neirijnck et al., 2018).
IGF1 has reversed testicular atrophy induced by cirrhosis of
the liver in rats (in which IGF1 levels are reduced), resulting in
full recovery of testicular weight and reversal of all histopatho-
logical abnormalities (Castilla-Cortazar et al., 2000). Although
specific abrogation of IIR signalling in germ cells did not appear
to impair testicular function in mice, there is evidence that germ
cell function is profoundly affected by IGF signalling. In keeping
with the recognized role of IGF1 as an inhibitor of apoptosis,
in vitro organ culture of mouse testicular fragments supple-
mented with IGF1 increased the density of germ cells by
decreasing apoptosis (Yao et al., 2017). Mice carrying a trans-
gene-expressing IGFBP1 exhibited defects in spermatogenesis
with altered production and quality of spermatozoa, attributed
to the lack of bio-available IGF1 caused by increased binding of
IGFBP1 (Froment et al., 2004). IGF1 administration was able to
reverse the decrease in germ cell numbers observed in rats with
surgically induced unilateral undescended testes (Bingol-Kolo-
glu et al., 2010). Co-culture of Leydig cells with mouse sper-
matogonial stem cells (SSCs) and subsequent blockade of IIR
signalling led to loss of expression of pluripotent genes in SSCs,
supporting the idea that IGF1 produced by Leydig cells can
maintain SSC pluripotency (Huang et al., 2009). IGF1 has also
been shown to influence steroidogenesis in cultured Leydig cells
(Lin et al., 1986). Insulin receptor substrate 2 (IRS2) is one of the
key downstream effectors of IIR signalling and has itself been
implicated in testicular development. Mice with homozygous
deletion of the IRS2 have reduced testicular weight with lower
numbers of Sertoli cells, spermatogonia and spermatocytes
(Griffeth et al., 2013).
In a zebrafish model, either ectopic overexpression of IGF-I or
dominant negative expression of IGF receptors in primordial
germ cells (the putative cells of origin in TGCT) leads to defects
in migration of these cells to the genital ridge (Sang et al., 2008).
A separate study found that knocking down the IGFR1b gene in
zebrafish embryos resulted in both mismigration and elimina-
tion of primordial germ cells (Schlueter et al., 2007). In C.ele-
gans, mutations in the daf-2 gene (the single gene encoding an
insulin/insulin-like growth factor receptor in this species) led to
infertility (Tissenbaum & Ruvkun, 1998) and a study using a con-
ditional daf-2 allele demonstrated the necessity of IIR signalling
for larval germ cell proliferation by promoting cell cycle progres-
sion (Michaelson et al., 2010). Together, these studies provide
evidence for an essential role of IGF signalling in supporting the
normal development of germ cells.
ROLE OF IGF SYSTEM IN CANCER RISK
There are several lines of long-standing evidence linking
higher serum levels of IGF1 (associated with increased growth)
and decreased serum levels of some IGFBPs (associated with
suppressing growth through binding IGF1) with additional can-
cer risk (reviewed in Crowe et al., 2011). The congenital over-
growth disorder, Beckwith–Wiedemann syndrome, is associated
with increased cancer risk and is frequently associated with dis-
rupted imprinting of the IGF2 gene. The gene encoding the
potent mitogen IGF2 is imprinted in normal somatic cells, with
Figure 1 Insulin and IGF ligand specificity for INSR/IGF1R receptors. Each of the insulin receptors INSR-A, INSR-B and IGF1R transcripts encodes a single
polypeptide chain, which undergoes proteolytic cleavage to produce an a and b subunit. Each ab subunit forms homo- or heterotetramers. Insulin and the
IGF ligands can bind competitively to these receptors as shown. Bioavailability of IGF ligands is regulated by insulin-like growth factor binding proteins 1–6
(IGFBPs). IGFBPs bound to ligands can also bind the acid labile subunit (ALS) in the bloodstream to form a ternary complex which is thought to be unable
to cross the capillary endothelium unless partially dissociated. Insulin signalling primarily affects glucose metabolism (but can also regulate other functions
including growth), signalling through the INSR-A homotetramer or any receptor containing IGF1R subunits results in downstream activation of pathways
involved in proliferation, prevention of apoptosis and migration. The structurally unrelated IGF2R receptor binds IGF2, the functional significance of which is
yet to be fully established but may act to regulate extracellular IGF2 levels.
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only the paternal allele being expressed. Loss of imprinting in
this chromosomal location results in increased IGF2 levels by
being biallelically expressed (Mussa et al., 2016).
It is noted that both height and body mass index (BMI) corre-
late with higher cancer risk and with increased circulating IGF1
levels and/or decreased IGFBP levels (Nunney, 2018). Consistent
with these findings, patients with congenital secondary IGF1
deficiency are less likely to develop cancer (Steuerman et al.,
2011), while mice with reduced circulating Igf1 levels experience
delayed onset of mammary tumours compared to controls (Wu
et al., 2003). In accordance with other tumour types, height has
also been reported as a risk factor for testicular germ cell
tumours (TGCTs) (Rasmussen et al., 2003; Richiardi et al., 2003;
McGlynn et al., 2007), although there is no direct evidence that
circulating IGF1 levels are linked to a higher risk of developing
TGCT. However, the chromosomal disorder Klinefelter syn-
drome (47 XXY) is associated with increased height (Aksglaede
et al., 2008) and an increased risk of mediastinal germ cell
tumours (Nichols et al., 1987) but serum IGF1 and IGFBP3 levels
in the normal range (Aksglaede et al., 2008).
Mice with elevated growth hormone (GH)/Igf1 serum concen-
tration had a higher incidence and reduced latency of mammary
tumours but only in the context of a high fat diet (Gahete et al.,
2014). Modulating factors such as diet perhaps explains the lack
of concordance in the literature when trying to assess the propor-
tion of risk attributable to circulating IGF1 concentration and
these factors may explicate the lack of such a relationship in
TGCT. A large meta-analysis examining the effects of circulating
IGF1 and IGFBP3 levels on the risk of developing several common
cancers detected an association between increased IGF1 concen-
tration and prostate, colorectal and pre-menopausal breast can-
cer risk, while perhaps surprisingly, increased IGFBP3 levels were
associated with risk of pre-menopausal breast cancer. This find-
ing challenges the assumption that IGFBP3 only exerts its effects
on cancer risk by regulating bioavailability of IGF1. This study did
not detect a protective effect of lower IGFBP3 levels overall; how-
ever, when one of the lung cancer cohorts was removed (that
recruited only heavy smokers and asbestos workers), the risk of
lung cancer was significantly decreased in individuals with higher
IGFBP3 concentration (Renehan et al., 2004). Overall, serum
levels of IGF ligands have a modest effect on cancer risk and may
need very large association or meta-studies to detect them. An
alternative mechanism for IIR activity to influence cancer risk
would be altered expression of the IGF1R receptor in the target
organ. In this regard, it is interesting to note that Igf1r concentra-
tion was higher in cryptorchid than normal testes post-puberty in
an induced rat model (Antich et al., 1995). Cryptorchidism is a
well-known risk factor for TGCT (Banks et al., 2013); however,
the status of IGF1R expression is unknown in this condition in
humans. Polymorphisms within IGF-related genes have also
been associated with risk of several cancers including breast and
prostate although these are not necessarily linked to differences
in circulating IGF levels (Al-Zahrani et al., 2006; Canzian et al.,
2006; Cao et al., 2014a; Jung et al., 2017). There is, however, no
positive evidence linking polymorphisms in IGF genes to testicu-
lar cancer risk (Chia et al., 2008; Loveday et al., 2018).
ROLE OF IGF SYSTEM IN ONCOGENESIS
Increased expression of many components of the IGF family
has been invoked in tumourigenic mechanisms. IGF1R, IGF1
and IGF2 are frequently overexpressed in a large number of
tumour types (Papa et al., 1993; Bergmann et al., 1995; Sekyi-
Otu et al., 1995; Steller et al., 1996; Weber et al., 2002). Insulin-
like growth factor 2 mRNA binding proteins (IMPs) are expressed
during embryogenesis and less so in normal adult tissues; how-
ever, they are upregulated in a broad range of cancers where
their expression correlates with poor prognosis (reviewed in
Degrauwe et al., 2016). Moreover, expression of IGF1R has been
shown to be prerequisite for transformation by several different
oncogenes (Sell et al., 1993; Toretsky et al., 1997). Several mem-
bers of the IGF family are potentially dysregulated in TGCT.
IGF1 and IGFBP5 are frequently expressed in the precursor
TGCT lesion, germ cell neoplasia in situ (Drescher et al., 1997).
Large-scale de novo demethylation takes place in primordial
germ cells, relaxing imprinting at most genomic locations.
TGCTs frequently retain this loss of imprinting, expressing IGF2
biallelically (Van Gurp et al., 1994), which has been linked to
increased tumour aggressiveness in other cancer types (Dam-
aschke et al., 2017). Increased serum levels of IGF2 and IGFBP2
have been found in non-seminomatous TGCT, decreasing upon
successful therapy and increasing again in cases of recurrence
(Fottner et al., 2008). Our group has recently shown that IGF1R
is expressed in approximately half of non-seminomas and influ-
ences survival of non-seminoma cells in vitro (Selfe et al., 2018).
The IGF axis has been implicated in a wide number of onco-
genic processes. Signalling through the IGF1R receptor primarily
activates the PI3K/AKT and MAPK (Ras/Raf/MEK/ERK) path-
ways. Whereas activation of the MAPK pathway drives cellular
proliferation through promoting proteins involved in cell cycle
progression, signalling via the AKT pathway both activates anti-
apoptotic proteins and inhibits anti-apoptotic proteins to
enhance cell survival (Chitnis et al., 2008). Our study in TGCT
cell lines suggested that these cells primarily signal through the
PI3K/AKT pathway in response to IGF ligand, perhaps reflecting
the activation of the MAPK pathway via other means such as the
tyrosine kinase receptor KIT and RAS mutation or overexpres-
sion (McIntyre et al., 2004, 2005). IGF2 can rescue a teratocarci-
noma cell line from undergoing apoptosis in the absence of
serum (Engstr€om, 2010), reinforcing the anti-apoptotic proper-
ties of IIR signalling in the context of TGCT.
IGF1R signalling has also been associated with several cellular
processes that contribute to metastasis. Migration and invasion
have been linked to IGF1R activity through co-operation with
the integrin pathway leading to Rho-A-dependent motility via
FAK and RACK1 (Doerr & Jones, 1996; Brooks et al., 1997; Zhang
et al., 2005; Montagnani Marelli et al., 2006). The chemokine
receptor CXCR4 (Goddard et al., 2007; Gilbert et al., 2009) is
reported to be involved in the survival and migration of TGCTs
as well as primordial germ cells (reviewed in Gilbert et al.,
2011a). Notably, IGF1 signalling through IGF1R has been shown
to increase migration and CXCR4 expression in both mesenchy-
mal stem cells and embryonic germline stem cells (Li et al.,
2007; Kuo et al., 2018).
Matrix metalloproteinases are induced by IGF1 (Yoon & Hurta,
2001), conferring an invasive phenotype (Das et al., 2018), and
MMP-2 and MMP-9 are frequently expressed in non-seminomas
(Gilbert et al., 2011b). IGF1 can also induce VEGF ligands and
upregulate vascular vessel formation, thereby exhibiting pro-an-
giogenic properties (Kurmasheva et al., 2009; Li et al., 2011).
IGF1R signalling appears to be required for epithelial-to-
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mesenchyme transition in some cancer cells (Graham et al.,
2008; Yi et al., 2018), driving malignant progression. It is per-
haps, therefore, unsurprising that IGF axis proteins have been
linked to patient outcome (Kawamoto et al., 1998; Fu et al.,
2011; Turney et al., 2011; Unger et al., 2017). Unlike other tyro-
sine kinase growth factor receptors, tumours have not been
found to harbour activating mutations in IGF1R, not even as a
resistance mechanism in response to IGF1R-targeted therapies.
ROLE OF IGF SYSTEM IN CHEMORESISTANCE
IGF1R activation has been implicated in resistance to both
chemical and radiation based therapies. Investigations in several
different tumour types have revealed increased IGF activity in
chemoresistant tumours and shown that IGF1R inhibition acts
as a chemosensitizer (Dallas et al., 2009; Eckstein et al., 2009;
Juan et al., 2011; Ireland et al., 2016; Cao et al., 2017). Down-
stream activation of the PI3K/AKT pathway has been shown to
be instrumental to the mechanism of chemoresistance in many
of these studies.
IGF1R has also been found in the nucleus. Intriguingly,
nuclear IGFR1 was increased in metastatic colorectal tumours
compared to matched primary tumours and correlated with
poor overall survival (Codony-Servat et al., 2017). Nuclear
translocation of IGFR1 requires ligand-based activation of the
receptor and can be blocked by IGF1R inhibitors (Aleksic et al.,
2010). Following entry into the nucleus, IGF1R has been shown
to interact with transcriptionally active regions of DNA including
the proto-oncogene JUN (Aleksic et al., 2018). It is currently
unknown whether IGF1R is found or plays a role in the nuclei of
TGCT cells.
Recent studies have suggested tumour-associated cells such as
tumour-associated macrophages (TAMs) and tumour-associated
endothelial cells (TECs) may co-operate in IGF-mediated
chemoresistance. TAMs and myofibroblasts were found to be
the main sources of IGF production in pancreatic cancer (Ire-
land et al., 2016). TECs were found to keep tumourigenesis in
check by secreting IGFBP7/angiomodulin, a direct IGF1R antag-
onist (binding to IGF1R itself and not IGF ligands) in the pres-
ence of IGF1. However, the administration of chemotherapy
appears to alter this process and IGFBP7 expression is sup-
pressed while IGF1 expression is enhanced, allowing the TECs to
be converted to promoters of tumourigenicity and consequently
the emergence of chemoresistance (Cao et al., 2017). The induc-
tion of chemotherapy itself initiates the conversion of TECs,
which perhaps perceive the chemotherapeutic agent in the same
way as an injury and switch their transcriptional programme in
response.
IGF1R expression is also associated with a radioresistant phe-
notype (Turner et al., 1997; Yu et al., 2003; Chen et al., 2017),
suggesting that it may have a role in DNA damage response and/
or repair. Several different mechanisms for the involvement of
IGF1R in radioresistance have been proposed. Nuclear IGF1R is
known to physically interact with and phosphorylate proliferat-
ing cell nuclear antigen (PCNA), a key mediator of the DNA dam-
age response (Waraky et al., 2017). A role for IGF1R has been
suggested in both of the major pathways for repairing DNA dou-
ble-strand breaks, namely homologous recombination and non-
homologous end joining (Chitnis et al., 2014). One of the main
downstream effectors of IGF1R signalling, insulin receptor sub-
strate 1 (IRS-1), has been shown to interact with RAD51 which
localizes to the sites of double-strand breaks and facilitates
repair by homologous recombination (Trojanek et al., 2003).
Although a link between IGF signalling in TGCT and DNA repair
has not been established in TGCT, modulation of DNA repair
capacity is associated with cisplatin resistance in TGCT
(Kalavska et al., 2018).
TGCT cells are considered the paradigm of a chemosensitive
tumour, readily undergoing apoptosis in response to DNA-dam-
aging agents such as cisplatin via a p53-dependent pathway. The
p53 response to DNA damage is intact but leads to apoptosis in
preference to cell cycle arrest, in part due to very low levels of
p21 in TGCT cells (Spierings et al., 2004). Nevertheless, although
the majority of TGCT patients respond to treatment initially, a
minority relapse with cisplatin refractory disease. Mutations in
the TP53 gene and amplification of its regulatory protein MDM2
are over-represented in cisplatin-resistant TGCT but do not
explain all cases (Bagrodia et al., 2016). We have recently
described increased IGF1R copy number, expression and activa-
tion (with increased phospho-AKT levels) in a model of acquired
cisplatin resistance (Selfe et al., 2018) which could subsequently
be resensitized to cisplatin upon reduction of IGF1R. IGF1R
hyperactivation has been specifically linked to cisplatin refrac-
tory ovarian cancer (Eckstein et al., 2009). There is additional
evidence signifying a role for the AKT pathway in platinum-resis-
tant TGCT. Inhibition of AKT can restore sensitivity to cisplatin-
resistant TGCT cells by re-localizing p21 from the cytoplasm to
the nucleus (Koster et al., 2010), while PIK3CA and AKT1 muta-
tions are exclusively found in cisplatin-resistant tumours (Feld-
man et al., 2014). Phospho-AKT levels are significantly higher in
cisplatin-resistant disease compared to sensitive or untreated
tumours (Juliachs et al., 2014). Copy number gain and concomi-
tant overexpression of AKT1 is a frequent event in intracranial
germ cell tumours, which, although clinically and histologically
similar to gonadal germ cell tumours, are more likely to be
refractory to treatment (Wang et al., 2014). Figure 2 summarizes
the key alterations in IGF signalling that have been observed in
cisplatin-resistant TGCT.
THERAPEUTIC TARGETING OF THE IGF SYSTEM IN
CANCER
IGF1R appears to represent an ideal therapeutic target in
many cancers; it is expressed on the cell surface, possesses enzy-
matic activity and has a role in many tumourigenic processes.
Two principal classes of inhibitor were initially used in a trial
setting: monoclonal antibodies against IGF1R (mAbs) and small
molecule tyrosine kinase inhibitors of IGF1R (TKIs). These inhi-
bitors to IGF1R were very enthusiastically explored in many clin-
ical trials as single agents two decades ago. Outcomes in these
trials were extremely disappointing due to an overall infre-
quency of objective responses and a lack of any accurate predic-
tive biomarkers of response. The most promising patient
subgroup who might benefit from IGF1R-targeted therapy are
Ewing’s sarcoma patients, where a minority have sustained dur-
able responses lasting several years without major side effects
(Anderson et al., 2016). The inability to select which patients are
likely to respond has severely hampered efforts to employ
IGFR1-targeted agents in mainstream treatment.
Several explanations have been proposed to explain the lack of
efficacy of IGF1R mAbs and TKIs (reviewed in Simpson et al.,
2017). There is a large amount of crosstalk between the
© 2019 The Institute of Cancer Research. Andrology published by Wiley Periodicals Inc on behalf of The
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signalling pathways of IGF1R and other RTKs such as EGFR,
ERBB2 and PDGFR (Browne et al., 2011; Liu et al., 2014). Cancer
cells may therefore be able to circumvent IGF1R inhibition by
upregulating another or several RTKs. As a corollary to this, it is
also true that upregulation of IGF1R signalling can act as an
escape mechanism in response to inhibitors of other RTKs (Ma
et al., 2016; Almiron Bonnin et al., 2017; Li et al., 2017). The
IGF1R mAbs will not prevent signalling via IGF2 binding to the
INSR-A receptor, which would be another route to evade IGF1R
inhibition; indeed, increased phospho-INSR levels have been
observed in response to an EGFR inhibitor in colorectal cancer
cells (Jones et al., 2006). IGF1R TKIs block activation of both
homotetrameric and heterotetrameric INSR and IGF1R due to
the similarity of the kinase regions in both proteins, and this
raises the potential problem of dose limitation in order to pre-
vent glucose metabolism being adversely affected. A newer gen-
eration of therapeutic antibodies against IGF ligands should
avoid both of these pitfalls by allowing insulin to signal normally
and preventing IGF2 from activating the INSR-A receptor. Tar-
geting the ligands instead of the receptors should also prevent
resistance through downregulation of inhibitory IGF binding
proteins such as IGFBP2 as seen in rhabdomyosarcoma cells
(Kang et al., 2014).
A major hurdle in the use of anti-IGF1R therapies in the clinic
has been the lack of suitable predictive biomarkers. There is con-
flicting evidence as to whether expression of IGF1R itself, as
opposed to activated IGF1R (phospho-IGF1R), identifies patients
that would benefit from IGF1R-targeted agents (Cao et al., 2008;
Kurmasheva et al., 2009; Zha et al., 2009; Cao et al., 2014b).
Expression of IGF1R or even presence of activated IGF1R does
not always signify cells that are susceptible to IGF1R inhibition.
This is seen in the case of the seminoma cell line, TCAM2 (Selfe
et al., 2018), which despite comparatively high basal levels of
activated IGF1R among TGCT cell lines was among the least
responsive to an IGF1R TKI. Expression of other components of
the IGF axis such as IRS2 and IGFBP5 has been shown to be
important for determining sensitivity to an IGF1R mAb (Pavlicek
et al., 2013). Exclusive nuclear IGF1R correlated with a better
outcome in sarcoma patients treated with an IGF1R mAb
(Asmane et al., 2012), indicating that nuclear staining in the
absence of cytoplasmic IGF1R may be a useful biomarker; how-
ever, this study had small numbers of patients.
In order to exploit the anti-tumourigenic responses to INSR/
IGF1R inhibition seen in preclinical experiments, current inves-
tigations are concentrating on combinatorial studies using IGF
inhibitors. Combination with other RTK TKIs is used as a means
of reducing the emergence of resistance or in addition to either
standard chemotherapeutic agents or radiotherapy utilizing
their properties as chemo- and radiosensitizers, respectively
(McDermott et al., 2017; Schaffrath et al., 2017). Given the
importance of the PI3K/AKT pathway in TGCT, simultaneous
multiple targeting of this pathway may be effective in TGCT
patients by combining IGF1R inhibition with other inhibitors of
this pathway. IGF1R inhibition used in conjunction with stan-
dard chemotherapy regimens may be effective in some TGCT
patients with cisplatin-resistant disease. Initial clinical testing of
this hypothesis would likely involve refractory patients for whom
existing treatment options were limited or unavailable. Attempt-
ing to resensitize patients to cisplatin at an earlier stage would
however be potentially more effective than in the heavily pre-
treated cases where multiple genetic events may have had time
to occur and establish resistance by different mechanisms. Care-
ful selection of cases may also be important as if PIK3CA or
AKT1 mutations are driving resistance, inhibition of the IGF sig-
nalling pathway should take place downstream of these. The
molecular pathways that allow IGF1R inhibitors to act as chemo-
or radiosensitizers are not yet fully understood. Identifying these
mechanisms and studying their interaction with the deficiencies
in DNA repair in TGCT cells will be necessary in order to exploit
the full benefit of targeting the IGF axis. The mTOR inhibitor,
everolimus, has shown limited efficacy in two phase-II studies of
unselected TGCT patients with refractory disease (Mego et al.,
2016; Fenner et al., 2019). This may be due to the pro-oncogenic
effects of INSR/IGF1R being at least in part independent of the
PI3K/AKT pathway downstream of mTOR or that IGF-targeted
therapies must be combined with DNA damaging agents to
achieve clinical utility in TGCT.
CONCLUDING COMMENTS
Primordial germ cells, the likely precursor of TGCT, require
IGF1R signalling for correct migration to the genital ridge, and
the IGF system has many roles in establishing and maintaining
testicular function including steroidogenesis and maintaining
pluripotency in spermatogonial stem cells. The IGF axis is dys-
regulated in many tumour types and can contribute to oncogen-
esis via multiple disparate mechanisms, making it an attractive
therapeutic target. The lack of mutations found in IGF proteins
in cancer may hint that INSR/IGF1R signalling is not a key driver
in many tumours, and together with cross talk between path-
ways, this could explain the lack of efficacy seen in clinical trials
using several different types of IGF1R-targeted agent. However,
Figure 2 IGF signalling pathway alterations occurring in cisplatin-resistant
TGCT. Several alterations in the IGF signalling pathway have been docu-
mented in cisplatin-resistant TGCT. PIK3CA and AKT1 activating mutations
have been found exclusively in resistant tumours. PTEN loss is a frequent
event occurring early in TGCT evolution. Cisplatin-resistant cells demon-
strate overexpression of AKT and phospho-AKT levels in comparison with
their sensitive counterparts, which results in increased translocation of p21
to the cytoplasm where it can inhibit apoptosis. IGF1R overexpression was
seen in an acquired model of resistance. Interestingly, PDGFRb has also
been shown to contribute to cisplatin resistance via PI3K/AKT signalling
with overexpression of PDGF-b.
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there are multiple lines of evidence to suggest that cancers can
use the INSR/IGF1R pathway as a resistance mechanism to other
treatments and that IGF1R inhibition can augment responses to
standard chemo- and radiotherapy. The clinical utility of block-
ing this pathway may therefore lie in combining newly designed
IGF ligand-targeted therapies with existing or new treatments.
TGCT cells commonly exhibit aberrant IGF axis activation
through elevated IGF1R activity (Selfe et al., 2018) and/or
increased IGF2 expression through loss of imprinting (Van Gurp
et al., 1994). We have shown that cells with high levels of IGF1R
activation are vulnerable to IGF1R inhibition. Cisplatin resis-
tance, the major cause of mortality in TGCT, may be impacted
by including IGF1R inhibition.
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